IDH1 — Targeted Therapies, Trials & Pipeline
IDH1 mutations produce oncometabolite 2-HG in AML, cholangiocarcinoma and glioma; targeted by selective IDH1 inhibitors.
IDH1 mutations produce oncometabolite 2-HG in AML, cholangiocarcinoma and glioma; targeted by selective IDH1 inhibitors.